Wilkin T J
Endocrine Section, Southampton General Hospital, United Kingdom.
N Engl J Med. 1990 Nov 8;323(19):1318-24. doi: 10.1056/NEJM199011083231906.
The discovery in 1956 of the long-acting thyroid stimulator of Graves' disease, now known as thyroid-stimulating antibodies, was seminal. A new mechanism for disease was revealed that appears applicable to virtually all endocrine systems, involving the growth as well as the function of endocrine cells. An endocrine gland may fail through at least three autoimmune mechanisms: destruction, atrophy, and inhibition of function. Destruction is probably irreversible but is not usually distinguishable clinically from receptor blockade causing atrophy or from metabolic unresponsiveness. The contribution made by receptor autoimmunity to endocrine diseases other than thyroid disease is at present unclear, but with immunologic manipulation it is potentially reversible, improving the replicative capacity of the gland, its metabolic responsiveness, or both.
1956年发现的格雷夫斯病长效甲状腺刺激素,即现在所知的甲状腺刺激抗体,具有开创性意义。它揭示了一种新的疾病机制,这种机制似乎适用于几乎所有内分泌系统,涉及内分泌细胞的生长和功能。内分泌腺功能减退可能至少通过三种自身免疫机制发生:破坏、萎缩和功能抑制。破坏可能是不可逆的,但在临床上通常无法与导致萎缩的受体阻断或代谢无反应性区分开来。目前尚不清楚受体自身免疫对甲状腺疾病以外的内分泌疾病的影响,但通过免疫调控,这种影响可能是可逆的,可提高腺体的复制能力、代谢反应性,或两者兼而有之。